AFM
ADAP

Anson Funds Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Anson Funds Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-103,282
Closed -$418K – 48
2016
Q4 		$418K Buy
+103,282
New +$495K 0.13% 46
2016
Q1 		– Sell
-30,737
Closed -$371K – 63
2015
Q4 		$371K Buy
+30,737
New +$301K 0.12% 48

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Anson Funds Management's ADAP Position: Q1 2017 in Review

Anson Funds Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2017, closing a stake of 103,282 shares — an estimated $418K sold.

Anson Funds Management first reported a position in ADAP in Q4 2015 and held it in 2 quarters. The position peaked at $418K in Q4 2016. 49 funds tracked by Wall St. Rank hold ADAP as of Q1 2017.

  • Anson Funds Management reported no remaining Adaptimmune Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Anson Funds Management sold 103,282 Adaptimmune Therapeutics shares in Q1 2017, an estimated $418K.
  • Anson Funds Management first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 2 quarters.
  • Anson Funds Management's Adaptimmune Therapeutics position peaked at $418K in Q4 2016.
  • 49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2017.

Based on Anson Funds Management's 13F filing for Q1 2017, filed 15 May 2017.